Table 2.
Univariate analysis of PFS and OS in 46 patients.
| Variables | PFS | OS | ||
|---|---|---|---|---|
| Univariate analysis | Univariate analysis | |||
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (years) | ||||
| <60 | Ref. | Ref. | ||
| ≥60 | 1.362 (0.734–2.527) | 0.328 | 1.036 (0.486–2.210) | 0.926 |
| Gender | ||||
| Male | Ref. | Ref. | ||
| Female | 1.048 (0.556–1.974) | 0.886 | 1.273 (0.589–2.752) | 0.540 |
| ECOG PS | ||||
| 0–1 | Ref. | Ref. | ||
| 2 | 1.240 (0.377–4.081) | 0.723 | 1.061 (0.251–4.491) | 0.936 |
| Primary site | ||||
| Colon | Ref. | Ref. | ||
| Rectum | 0.509 (0.168–1.541) | 0.232 | 0.875 (0.333–2.305) | 0.788 |
| Unknown | 0.615 (0.163–2.325) | 0.474 | 0.668 (0.207–2.157) | 0.500 |
| Metastatic organs | ||||
| 1–2 | Ref. | Ref. | ||
| ≥3 | 1.703 (0.886–3.275) | 0.110 | 1.993 (0.134–7.376) | 0.398 |
| RAS mutant | ||||
| Yes | Ref. | Ref. | ||
| No | 1.225 (0.518–2.896) | 0.644 | 1.494 (0.494–4.519) | 0.477 |
| Unknown | 1.805 (0.690–4.723) | 0.229 | 1.867 (0.559–6.232) | 0.310 |
| Lines of previous therapy | ||||
| 2 | Ref. | Ref. | ||
| ≥3 | 1.187 (0.589–2.392) | 0.631 | 1.830 (0.691–4.844) | 0.188 |
| Previous Bevacizumab | ||||
| Yes | Ref. | Ref. | ||
| No | 1.017 (0.446–2.319) | 0.968 | 2.659 (0.997–7.091) | 0.051 |
| Previous anti-VEGFR | ||||
| Yes | Ref. | Ref. | ||
| No | 2.423 (1.245–4.715) | 0.009 | 1.004 (0.438–2.303) | 0.992 |
| Sufficient Treatment* | ||||
| Yes | Ref. | Ref. | ||
| No | 1.093 (0.584–2.045) | 0.782 | 1.236 (0.577–2.650) | 0.586 |
| NLR | ||||
| ≤3 | Ref. | Ref. | ||
| >3 | 1.976 (1.061–3.682) | 0.032 | 2.332 (1.085–5.011) | 0.030 |
| PLR | ||||
| >300 | Ref. | Ref. | ||
| 150–300 | 0.659 (0.283–1.534) | 0.333 | 1.122 (0.425–2.962) | 0.816 |
| <150 | 0.570 (0.234–1.385) | 0.214 | 0.396 (0.137–1.147) | 0.088 |
| CEA | ||||
| ≤5 | Ref. | Ref. | ||
| >5 | 1.308 (0.506–3.382) | 0.579 | 1.072 (0.321–3.577) | 0.910 |
| Hand-foot syndrome | ||||
| Yes | Ref. | Ref. | ||
| No | 2.153 (1.077–4.304) | 0.030 | 1.262 (0.565–2.814) | 0.570 |
| Hypertension | ||||
| Yes | Ref. | Ref. | ||
| No | 1.796 (0.869–1.796) | 0.114 | 1.291 (0.545–3.060) | 0.562 |
| Fatigue | ||||
| Yes | Ref. | Ref. | ||
| No | 1.128 (0.544–2.340) | 0.746 | 1.987 (0.750–5.264) | 0.167 |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; VEGFR, vascular endothelial growth factor receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio, CEA, carcinoembryonic antigen.
*Fruquintinib was administered without dose reduction, treatment interruption, or therapy discontinuation.